Risk alert: FDA restricts sale of Essure Permanent Birth Control

April 9, 2018

The FDA has restricted the sale and distribution of the Essure Permanent Birth Control System to only physicians and health care facilities that agree to use the FDA-approved “Patient-Doctor Discussion Checklist — Acceptance of Risk and Informed Decision Acknowledgement.”

Health care professionals must review this checklist with patients and give them the opportunity to sign it before Essure implantation.    

This new safety measure has been enacted to ensure that women who receive Essure have been informed of the risks and benefits of the device. 

Learn more

 

Previous Article
Why the Facebook scandal should have you analyzing your third-party vendors
Why the Facebook scandal should have you analyzing your third-party vendors

Next Flipbook
Reporter Quarter 1 2018
Reporter Quarter 1 2018

Transgender health care (CME); Compassionate health care: 2017 Legislative highlights; Failure to correctly...